Puma Biotechnology Total Current Liabilities

Puma Biotechnology (PBYI) currently reports a total current liabilities of $50M as of June 2026. That compares with $79M in the prior-year period — down 37.0% year over year. Use the charts on this page to explore Puma Biotechnology's total current liabilities history and peer comparisons.

Puma Biotechnology's total current liabilities decreased from $79M to $50M — a 37.0% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Puma Biotechnology reported $50M in total current liabilities as of June 2026. That compares with $79M in the prior-year period — down 37.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total current liabilities of $50M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Puma Biotechnology, and consider following PBYI for alerts when major investors trade the stock.

Puma Biotechnology is classified in the Healthcare sector. On total current liabilities, it currently shows $50M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing PBYI with unrelated industries.